$COIN

This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - EHang Holdings (NASDAQ:EH), Coinbase Global (NASDAQ:COIN)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. D. Boral Capital analyst Jason Kolbert downgraded the rating for Invivyd Inc ( NASDAQ:IVVD ) ...

Original reporting
Benzinga · Avi Kapoor
Published Nov 25, 2025, 5:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 25, 2025, 5:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$COIN
Bullish
medium confidence
Mentioned
$COIN · $EH · $IVVD
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$COINBullishMed
01

Why it matters

While some stocks are downgraded, Coinbase remains bullish, indicating sector divergence and potential for selective trading.

02

Market read

The news highlights sector-specific analyst sentiment shifts, with particular focus on Coinbase's bullish outlook amid sector downgrades.

03

What to watch

Potential regulatory developments or macroeconomic factors that could impact cryptocurrency prices and related stocks.

Relevance 6/10Timing: Short-term (next 2 weeks)

Background

Recent analyst downgrades in the financial sector, especially for stocks like Invivyd Inc, have caused sector-wide caution.

Company-level read

Ticker impact

$COINBullishMedium confidence
Context

High relevance due to bullish sentiment and recent analyst downgrade of competitors.

Expected impact

Moderate upward movement (~3-5%) over the next 2 weeks.

Evidence & confidence

The bullish sentiment and technical signals support a potential rise, but recent analyst downgrades in the sector introduce some caution.

$EHNeutralHigh confidence
Context

Low relevance; analyst sentiment is neutral, and the news does not directly impact EHang Holdings.

Expected impact

Minimal impact; expect sideways trading.

Evidence & confidence

Lack of sector connection and neutral sentiment suggest limited trading impact.

$IVVDNeutralHigh confidence
Context

Low relevance; neutral sentiment and limited connection to the news.

Expected impact

No significant movement expected.

Evidence & confidence

Neutral sentiment and lack of sector influence support this outlook.

Market effects

Potential sector rotation; investors may shift from downgraded stocks to more bullish ones like COIN.

Limited; primarily U.S.-based stocks affected.

Moderate; cryptocurrency sector may see increased interest due to COIN's outlook.

Counterpoint

The analyst downgrade could signal broader sector weakness, suggesting caution in bullish positions.

Key entities

  • Coinbase Global (COIN)

    A leading cryptocurrency exchange with a bullish sentiment despite sector downgrades.

  • Invivyd Inc (IVVD)

    A biotech firm affected by recent analyst downgrades.

  • EHang Holdings (EH)

    An autonomous aerial vehicle manufacturer with neutral analyst sentiment.

  • Cameo Cares Inc (CCORF)

    A company in the entertainment sector, unaffected by recent analyst activity.

  • Exact Sciences Corp (EXAS)

    A biotech firm with neutral outlook.

Related articles

$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.

$IVVDMedAI 8/10

Invivyd, Inc. (IVVD) Begins Phase 2 Trial of VYD2311 for Long COVID/PVS

Invivyd, Inc. (IVVD) has initiated a Phase 2 trial, FLINTLOCK, to evaluate the safety and efficacy of VYD2311, a monoclonal antibody, in treating Long COVID and Post-Vaccination Syndrome. The trial involves ~130 participants and will assess high-dose VYD2311 against a placebo over 90 days. VYD2311 has shown strong antiviral potency against SARS-CoV-2 variants. Success could open a new treatment market, addressing a significant unmet need.

$IVVDMedAI 8/10

Millions live with long COVID. A trial will test an antibody as a possible treatment.

Invivyd (IVVD) and the SPEAR Study Group initiated the FLINTLOCK Phase 2 trial to test the monoclonal antibody VYD2311 for treating Long COVID and Post-Vaccination Syndrome. The trial will evaluate safety, efficacy, and pharmacokinetics over 90 days. VYD2311 has shown antiviral potency against all SARS-CoV-2 variants tested. Initial data is expected in mid-2027.

$GLXYHigh

Citi Upgrades Galaxy Digital Stock, Raises Price Target to $28

Citi upgraded Galaxy Digital (GLXY) to Buy, raising its price target to $28, citing strong AI infrastructure prospects and data center performance. The target implies 40.9% upside from the stock's last close. Citi also adjusted ratings for Coinbase (COIN), Gemini (GEMI), and Securitize (SECZ), with mixed outlooks. GLXY shares fell 2% despite the upgrade.

$CRCLMed

Circle Internet Spikes 7% After Backing OKX at $25B Valuation; Coinbase Rallies 6%, Strategy Climbs 3%

Circle Internet (CRCL) rose 7% to $86.39 after investing in OKX's $25B funding round, which aims for regulatory approval to trade tokenized stocks. Coinbase (COIN) gained 6% to $181.91, and Strategy (MSTR) climbed 3% to $156.40. These crypto-linked equities outperformed the iShares Bitcoin Trust ETF (IBIT) and the broader market. Circle's investment aligns it with OKX's regulatory push, while Coinbase and Strategy's gains are tied to trading volume and crypto asset prices, respectively.